No Data
Kyorin Pharmaceutical To Go Ex-Dividend On September 27th, 2024 With 20 JPY Dividend Per Share
September 26th (Japan Standard Time) - $Kyorin Pharmaceutical(4569.JP)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 20 JPY dividend per
Sasumed Research Memo (2): aiming to continue providing sustainable veterinary services to society through the use of ICT.
■Company Overview 1. Company overview SassMed <4263> aims to provide sustainable veterinary services to society by utilizing ICT, proposing new treatment methods, optimizing development costs through the streamlining of the drug discovery process, and enhancing the efficiency of the entire pharmaceutical industry value chain through the use of medical data. It is a venture company in the research and development stage developing DTx, which is gaining attention as the third treatment method following pharmaceuticals and medical devices. The origin of the company name is "
In the DTx product business for the fiscal year ending June 2024, Sasmed will continue to promote the development of therapeutic applications.
On the 9th, Sasmeeed <4263> released its financial results for the fiscal year ending June 2024. Business revenue decreased by 35.4% compared to the previous period to 0.342 billion yen, operating loss was 0.364 billion yen (compared to a loss of 0.048 billion yen in the previous period), ordinary loss was 0.357 billion yen (compared to a loss of 0.044 billion yen in the same period), and net loss for the year was 0.357 billion yen (compared to a loss of 0.05 billion yen in the same period). The business revenue of the DTx product business was 0.2 billion yen (0.4 billion yen in the same period last year), and the segment profit was 0.055 billion yen (profit of 0.256 billion yen in the same period). Treatment.
List of conversion stocks (Part 3) [List of parabolic signal conversion stocks]
List of sell conversion stocks in the market. Code Company Name Closing Price SAR Tokyo Prime <4534> Mot-Phar. 3215 <3545> Fussoh-Yak. 2111 <4548> Sei-Kagaku. 809 <4559> Zeria-Nyu. 2115 <4568> Daiichi Sankyo.
Panasonic's operating profit for the first quarter decreased by 7.3% to 83.7 billion yen.
Panasonic <6752> announced its Q1 FY2025 performance, with revenue of 2.121689 trillion yen, a 4.5% YoY increase, and operating profit of 83.761 billion yen, a 7.3% YoY decrease. It fell short of consensus estimate (about 94.2 billion yen). Sales from the Living Solutions segment were 868 billion yen (a 4% YoY increase), Automotive segment revenue was 363.6 billion yen (a 7% YoY increase), and Connected Solutions segment revenue was 297.9 billion yen (a 13% YoY increase). [Positive]
Kyorin Pharmaceutical: Supplementary financial data for the first quarter of the March 2025 period.
No Data
No Data